Table 2.
Differences at the time of enrollment between patients with and without a history of CVD.
| Variables | Patients with CVD (n = 76, 36.4%) |
Patients without CVD (n = 133, 63.6%) |
p Value |
|---|---|---|---|
| Sex (M/F) | 67/9 (88.2%/11.8%) | 85/48 (63.9%/36.1%) | <0.001 |
| Age (years) | 69 (12) 68.4 ± 8.5 |
63 (16) 63.2 ± 11.5 |
0.002 |
| Weight (Kg) | 90 (25) 93 ± 18 |
84 (26) 78 ± 20.7 |
0.018 |
| BMI (Kg/m2) | 29.4 (8.4) 30.7 ± 5.4 |
28.9 (8.3) 30.4 ± 6.1 |
0.475 |
| HbA1c (%) | 7.5 (38) 7.6 ± 1.6 |
7 (2.8) 7.8 ± 2.1 |
0.938 |
| LDL (mg/dL) | 76 (38) 78.1 ± 34.6 |
105 (56) 103.4 ± 43.5 |
<0.001 |
| HDL (mg/dL) | 42 (15) 42.9 ± 12.1 |
44 (15) 44.8 ± 10.3 |
0.125 |
| Tg (mg/dL) | 120 (89) 161.1 ± 103.4 |
158 (106) 182.7 ± 127.9 |
0.215 |
| FIB-4 | 1.1 (0.67) 1.26 ± 0.54 |
0.97 (0.49) 1.08 ± 0.5 |
0.012 |
| Metformin | 48 (63.2%) | 105 (77.2%) | 0.015 |
| DPP-4 inhibitors | 17 (22.4%) | 30 (22.6%) | 0.975 |
| SGLT-2 inhibitors | 31 (40.8%) | 33 (24.8%) | 0.019 |
| GLP-1 analogs | 33 (43.4%) | 36 (27.1%) | 0.021 |
| Sulfonylureas | 7 (9.2%) | 15 (11.3%) | 0.815 |
| Pioglitazone | 4 (5.3%) | 3 (2.3%) | 0.259 |
| Insulin | 30 (39.5%) | 49 (36.8%) | 0.767 |
| Hypertension | 54 (71.1%) | 22 (16.5%) | <0.001 |
| FIB-4 > 1.3 | 29 (38.2%) | 30 (22.6%) | 0.025 |
Variables are expressed as median value and interquartile range (IQR) or number of cases (percentages). (Mean value ± standard deviation (SD) is presented underneath.) M/F: male/female; BMI: body mass index; HbA1c: glycated hemoglobulin A1; LDL: low-density lipoprotein; HDL: high-density lipoprotein; Tg: triglycerides; DPP-4: dipeptidyl peptidase-4; SGLT-2: Sodium-Glucose Transport Protein-2; GLP-1: glucagon-like peptide-1; CVD: cardiovascular disease. The table displays patients’ lipid values and antidiabetic treatment at the study's enrollment time.